The Rosen Law Firm announces that it is investigating potential securities claims against Arrowhead Research Corp. (NASDAQ:ARWR) resulting from allegations that the Company may have issued materially misleading business information to the investing public.

On October 8, 2014, Arrowhead Research released disappointing data from its experimental hepatitis B therapy ARC-520. On that same day, an article published on TheStreet.com reported that Arrowhead Research CEO Chris Anzalone and his team knew for months that ARC-520 dosed at 1 mg/kg and 2 mg/kg yielded 0.2-log and 0.3-log reductions in hepatitis B viral load. Yet, Arrowhead executives led investors to believe that ARC-520 was more potent and achieved viral load reductions in the range of 0.7 log or higher. On this news, shares of Arrowhead Research fell $5.48 per share, or over 43%, to close at $7.03 per share on October 8, 2014.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Arrowhead Research shareholders as a result of this adverse information. If you purchased Arrowhead Research stock on or before October 8, 2014, please visit the website at http://rosenlegal.com/cases-392.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010